NCT03399786: A reported trial by Regeneron Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03399786 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 18, 2018 |
| Completion date | June 10, 2019 |
| Required reporting date | June 10, 2022, midnight |
| Actual reporting date | Feb. 12, 2021 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |